- Equillium announced **Board of Directors and senior leadership changes** effective **October 1, 2025**, and other corporate updates on **October 6, 2025**.  **[1746466_ff3a5f2bfec64973bd3fd9ca1b2cedad_0]** 
- **Stephen Connelly, Ph.D.** was promoted to **President** in addition to his Chief Scientific Officer role, and **Daniel M. Bradbury** transitioned from Executive Chairman to **Chairman of the Board**.  **[1746466_ff3a5f2bfec64973bd3fd9ca1b2cedad_0]** 
- The company is sharpening its therapeutic pipeline focus on advancing **EQ504**, a novel aryl hydrocarbon receptor modulator, into the clinic to treat severe inflammatory diseases.  **[1746466_ff3a5f2bfec64973bd3fd9ca1b2cedad_0]** **[1746466_ff3a5f2bfec64973bd3fd9ca1b2cedad_1]** 
- The collaboration and license agreement with Biocon for **itolizumab** was terminated on **September 30, 2025**, as Equillium no longer intends to develop itolizumab.  **[1746466_ff3a5f2bfec64973bd3fd9ca1b2cedad_0]**

Equillium (EQ)